Mobile

A multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of oral dosing with GW679769 (50 mg or 150 mg) for 3 consecutive days in conjuncti...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000369-37

A multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of oral dosing with GW679769 (50 mg or 150 mg) for 3 consecutive days in conjunction with a single intravenous dose of ondansetron for the prevention of post-operative and post-discharge nausea and vomiting in at risk females undergoing laparoscopic/laparotomic surgical procedures

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the antiemetic dose of oral GW679769 (0 mg, 50 mg, or 150 mg), when administered for three consecutively days in combination with a single IV dose of ondansetron hydrochloride 4 mg administered on the day of surgery, that provides incremental improvement of the prevention of emesis (defined as vomiting or retching) during the first 72 hours following the emergence from anesthesia in female subjects undergoing laparoscopic/laparotomic surgical procedures who are predicted to have a high emetogenic risk.

Critère d'inclusion

  • Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV)

Liens